These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20191037)

  • 1. Post-prandial lipid levels for assessing target goal achievement in type 2 diabetic patients taking statin.
    Kim M; Suk J; Kim H; Jung H; Kim T; Park J
    J Korean Med Sci; 2010 Mar; 25(3):387-92. PubMed ID: 20191037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
    Querton L; Buysschaert M; Hermans MP
    J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term modest weight loss on fasting and post-prandial lipoprotein sub-fractions in type 2 diabetes mellitus patients.
    Ybarra J; James RW; Makoundou V; Bioletto S; Golay A
    Diabetes Metab; 2001 Dec; 27(6):701-8. PubMed ID: 11852380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of different statin therapy to change low-density lipoprotein cholesterol and high-density lipoprotein cholesterol level in Korean patients with and without diabetes.
    Khang AR; Song YS; Kim KM; Moon JH; Lim S; Park KS; Jang HC; Choi SH
    J Clin Lipidol; 2016; 10(3):528-537.e3. PubMed ID: 27206940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between nonfasting and fasting lipid measurements in patients with or without type 2 diabetes mellitus receiving treatment with 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
    Weiss R; Harder M; Rowe J
    Clin Ther; 2003 May; 25(5):1490-7. PubMed ID: 12867223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fasting cholesteryl ester transfer protein concentration is independently associated with the postprandial decrease in high-density lipoprotein cholesterol concentration after fat-rich meals: the Hoorn prandial study.
    Alssema M; El-Harchaoui K; Schindhelm RK; Diamant M; Nijpels G; Kostense PJ; Teerlink T; Heine RJ; Dallinga-Thie GM; Kuivenhoven JA; Dekker JM; Scheffer PG
    Metabolism; 2010 Jun; 59(6):854-60. PubMed ID: 20005542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Persistent lipid abnormalities in statin-treated patients and predictors of LDL-cholesterol goal achievement in clinical practice in Europe and Canada.
    Gitt AK; Drexel H; Feely J; Ferrières J; Gonzalez-Juanatey JR; Thomsen KK; Leiter LA; Lundman P; da Silva PM; Pedersen T; Wood D; Jünger C; Dellea PS; Sazonov V; Chazelle F; Kastelein JJ;
    Eur J Prev Cardiol; 2012 Apr; 19(2):221-30. PubMed ID: 21450578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of Attainment of Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol Goals in Cardiovascular Clinical Practice (from the National Cardiovascular Data Registry PINNACLE Registry).
    Spinler SA; Cziraky MJ; Willey VJ; Tang F; Maddox TM; Thomas T; Dueñas GG; Virani SS;
    Am J Cardiol; 2015 Aug; 116(4):547-53. PubMed ID: 26089010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study.
    Ting RZ; Yang X; Yu LW; Luk AO; Kong AP; Tong PC; So WY; Chan JC; Ma RC
    Cardiovasc Diabetol; 2010 Nov; 9():77. PubMed ID: 21092182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.
    da Silva PM
    Am J Cardiovasc Drugs; 2011; 11(2):93-107. PubMed ID: 21446776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustained postprandial decrease in plasma levels of LDL cholesterol in patients with type-2 diabetes mellitus.
    Lund SS; Petersen M; Frandsen M; Smidt UM; Parving HH; Vaag AA; Jensen T
    Scand J Clin Lab Invest; 2008; 68(7):628-40. PubMed ID: 19378436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, prospective, randomized, double-blind study to evaluate the safety and efficacy of Saroglitazar 2 and 4 mg compared with placebo in type 2 diabetes mellitus patients having hypertriglyceridemia not controlled with atorvastatin therapy (PRESS VI).
    Jani RH; Pai V; Jha P; Jariwala G; Mukhopadhyay S; Bhansali A; Joshi S
    Diabetes Technol Ther; 2014 Feb; 16(2):63-71. PubMed ID: 24138536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in high-density-lipoprotein cholesterol upon statin treatment in type 2 diabetic patients: a meta-analysis.
    Chang YH; Lin KD; Shin SJ; Lee YJ
    Nutr Metab Cardiovasc Dis; 2014 Oct; 24(10):1067-73. PubMed ID: 24880740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS).
    Charlton-Menys V; Betteridge DJ; Colhoun H; Fuller J; France M; Hitman GA; Livingstone SJ; Neil HA; Newman CB; Szarek M; DeMicco DA; Durrington PN
    Clin Chem; 2009 Mar; 55(3):473-80. PubMed ID: 19147732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.